British American Tobacco (BATS LN) says "we expect to grow New Category revenue by mid-teens through to 2030", adds that it is on track for full-year 2026 guidance, and reiterates it will be on the lower end of the 3-5% rev. target

Commentary of this kind from BAT typically surfaces through an investor day or management update rather than a formal results statement, and the historical pattern has been for the market to weigh the growth pitch against the twin drags of declining cigarette volumes and regulatory uncertainty around next-generation products. The mid-teens New Category target matters because that segment, spanning vapes like Vuse, heated tobacco like glo, and oral nicotine like Velo, is the valuation battleground relative to Philip Morris International, whose IQOS franchise has traditionally set the pace in reduced-risk products. The offsetting phrase, the lower end of the 3 to 5 percent total revenue ambition, quietly acknowledges the pressure on combustibles and the ongoing cost of building out new product lines. In comparable episodes, the share reaction hinges less on the ambition itself than on the granularity that accompanies it: the cadence of New Category volume growth, the path to profitability in that segment, and any fresh signal on the US regulatory environment for menthol and next-generation products. The affirmation that full-year 2026 guidance remains on track supplies the near-term anchor, which is typically what the market fixes on in the absence of a specific operating catalyst. Absent a surprise on figures or timing, updates of this kind tend to be absorbed as reinforcement of the established equity story rather than a fresh pricing signal.